AYTU BIOPHARMA, INC Increase (Decrease) in Accrued Liabilities
AYTU BIOPHARMA, INC (AYTU) reported Increase (Decrease) in Accrued Liabilities of -$3.13 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-09-22
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $935.00K.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$5.89M, a 466.27% decline year-over-year.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $3.46M, a 52.72% decline year-over-year.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$1.64M.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for fiscal 2026 was -$3.13M, a 453.50% decline from fiscal 2025.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for fiscal 2025 was $886.00K.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for fiscal 2024 was -$9.16M, a 354.12% decline from fiscal 2023.
- AYTU BIOPHARMA, INC increase (decrease) in accrued liabilities for fiscal 2023 was $3.60M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $935.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$4.95M derived: sum of 2 quarters · filed 2026-09-22 | -$1.50M derived: sum of 3 quarters · filed 2026-09-22 | -$3.13M 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | -$5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | -$2.43M derived: sum of 2 quarters · filed 2026-05-13 | -$4.07M 10-Q · filed 2026-05-13 | -$7.13M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-12-31 | $3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $1.82M 10-Q · filed 2026-02-03 | -$1.24M derived: sum of 3 quarters · filed 2026-09-22 | $364.00K derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-09-30 | -$1.64M 10-Q · filed 2025-11-13 | -$4.70M derived: sum of 2 quarters · filed 2026-09-22 | -$3.09M derived: sum of 3 quarters · filed 2026-09-22 | $4.22M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-06-30 | -$3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$1.46M derived: sum of 2 quarters · filed 2026-09-22 | $5.86M derived: sum of 3 quarters · filed 2026-09-22 | $886.00K 10-K · filed 2026-09-22 | ||||
| 2025-03-31 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $8.92M derived: sum of 2 quarters · filed 2026-05-13 | $3.95M 10-Q · filed 2026-05-13 | -$1.82M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $7.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $2.34M 10-Q · filed 2026-02-03 | -$3.43M derived: sum of 3 quarters · filed 2026-02-03 | -$3.27M derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-09-30 | -$4.97M 10-Q · filed 2025-11-13 | -$10.74M derived: sum of 2 quarters · filed 2025-11-13 | -$4.97M 10-Q · filed 2024-11-13 | -$8.96M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | -$5.61M derived: sum of 2 quarters · filed 2025-09-23 | -$4.00M derived: sum of 3 quarters · filed 2025-09-23 | -$9.16M 10-K · filed 2025-09-23 | -$9.57M 10-K · filed 2024-09-26 | |||
| 2024-03-31 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $1.78M derived: sum of 2 quarters · filed 2025-05-14 | -$3.39M 10-Q · filed 2025-05-14 | -$3.77M 10-Q · filed 2024-05-15 | -$6.82M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$3.55M 10-Q · filed 2025-02-12 | -$3.93M 10-Q · filed 2024-02-14 | -$6.98M derived: sum of 3 quarters · filed 2025-02-12 | $1.06M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-09-30 | -$5.17M 10-Q · filed 2023-11-14 | -$8.59M derived: sum of 2 quarters · filed 2024-09-26 | -$4.83M 10-Q · filed 2024-11-13 | $1.92M derived: sum of 4 quarters · filed 2024-09-26 | ||||
| 2023-06-30 | -$3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $4.61M derived: sum of 2 quarters · filed 2024-09-26 | $7.09M derived: sum of 3 quarters · filed 2024-09-26 | $3.60M 10-K · filed 2024-09-26 | ||||
| 2023-03-31 | $8.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $10.51M derived: sum of 2 quarters · filed 2024-05-15 | $7.03M 10-Q · filed 2024-05-15 | -$7.51M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$1.01M 10-Q · filed 2024-02-14 | -$15.55M derived: sum of 3 quarters · filed 2024-02-14 | -$13.68M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-09-30 | -$3.48M 10-Q · filed 2023-11-14 | -$18.02M derived: sum of 2 quarters · filed 2023-11-14 | -$16.16M derived: sum of 3 quarters · filed 2023-11-14 | -$20.10M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$14.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | -$12.68M derived: sum of 2 quarters · filed 2023-10-12 | -$16.62M derived: sum of 3 quarters · filed 2023-10-12 | -$13.29M 10-K · filed 2023-10-12 | ||||
| 2022-03-31 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$2.07M derived: sum of 2 quarters · filed 2023-05-11 | $1.25M 10-Q · filed 2023-05-11 | $4.32M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$3.94M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | -$616.00K 10-Q · filed 2023-02-21 | $2.45M derived: sum of 3 quarters · filed 2023-02-21 | -$1.12M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-09-30 | $3.33M 10-Q/A · filed 2023-02-21 | $6.39M derived: sum of 2 quarters · filed 2023-02-21 | $2.83M derived: sum of 3 quarters · filed 2023-02-21 | $4.94M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | -$500.00K derived: sum of 2 quarters · filed 2022-09-27 | $1.62M derived: sum of 3 quarters · filed 2022-09-27 | $771.00K 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | -$3.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$1.45M derived: sum of 2 quarters · filed 2022-05-16 | -$2.29M 10-Q · filed 2022-05-16 | -$5.56M 10-Q · filed 2021-05-17 | -$3.71M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $1.27M 10-Q · filed 2022-02-14 | $1.71M 10-Q · filed 2021-02-11 | -$145.32K derived: sum of 3 quarters · filed 2022-02-14 | $6.47M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | -$845.00K 10-Q · filed 2021-11-15 | $412.33K 10-Q · filed 2020-11-12 | -$2.26M derived: sum of 2 quarters · filed 2021-11-15 | $4.35M derived: sum of 3 quarters · filed 2021-11-15 | $4.50M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $5.20M derived: sum of 2 quarters · filed 2021-09-28 | $5.34M derived: sum of 3 quarters · filed 2021-09-28 | $5.34M 10-K · filed 2021-09-28 | $4.33M 10-K · filed 2020-10-06 | |||
| 2020-03-31 | $6.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | $6.76M derived: sum of 2 quarters · filed 2021-05-17 | $6.76M 10-Q · filed 2021-05-17 | $6.96M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $142.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $145.47K 10-Q · filed 2021-02-11 | $348.95K derived: sum of 3 quarters · filed 2021-02-11 | $346.53K derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-09-30 | $3.44K 10-Q · filed 2020-11-12 | $206.93K derived: sum of 2 quarters · filed 2020-11-12 | $204.50K derived: sum of 3 quarters · filed 2020-11-12 | $722.33K derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $203.49K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $201.06K derived: sum of 2 quarters · filed 2020-10-06 | $718.89K derived: sum of 3 quarters · filed 2020-10-06 | $961.86K 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | -$2.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $515.40K derived: sum of 2 quarters · filed 2020-05-15 | $758.37K 10-Q · filed 2020-05-15 | $586.26K 10-Q · filed 2019-05-14 | $732.84K derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $517.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $760.80K 10-Q · filed 2020-02-14 | $746.81K 10-Q · filed 2019-02-07 | $735.26K derived: sum of 3 quarters · filed 2020-02-14 | $689.05K derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-09-30 | $242.97K 10-Q · filed 2019-11-14 | $217.44K derived: sum of 2 quarters · filed 2019-11-14 | $171.22K derived: sum of 3 quarters · filed 2019-11-14 | -$474.54K derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | -$25.53K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | -$71.75K derived: sum of 2 quarters · filed 2019-09-26 | -$717.50K derived: sum of 3 quarters · filed 2019-09-26 | -$596.65K 10-K · filed 2019-09-26 | ||||
| 2018-03-31 | -$46.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14 | -$691.97K derived: sum of 2 quarters · filed 2019-05-14 | -$571.12K 10-Q · filed 2019-05-14 | -$839.40K derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | -$645.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14 | -$524.90K 10-Q · filed 2019-05-14 | -$793.18K derived: sum of 3 quarters · filed 2019-05-14 | -$701.08K derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-09-30 | $120.85K 10-Q · filed 2018-11-07 | -$147.43K derived: sum of 2 quarters · filed 2018-11-07 | -$55.33K derived: sum of 3 quarters · filed 2018-11-07 | $204.80K derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-06-30 | -$268.28K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | -$176.18K derived: sum of 2 quarters · filed 2018-09-06 | $83.95K derived: sum of 3 quarters · filed 2018-09-06 | -$414.57K 10-K · filed 2018-09-06 | ||||
| 2017-03-31 | $92.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | $352.23K derived: sum of 2 quarters · filed 2018-05-14 | -$146.29K 10-Q · filed 2018-05-14 | $847.31K derived: sum of 4 quarters · filed 2018-05-14 | ||||
| 2016-12-31 | $260.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | -$238.40K 10-Q · filed 2018-02-08 | $755.21K derived: sum of 3 quarters · filed 2018-02-08 | |||||
| 2016-09-30 | -$498.52K 10-Q · filed 2017-11-09 | $495.09K derived: sum of 2 quarters · filed 2017-11-09 | ||||||
| 2016-06-30 | $993.60K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $925.23K 10-K · filed 2017-08-31 | ||||||
| 2016-03-31 | -$68.37K 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |